Abstract
Stem cell technology holds the potential to offer new therapeutic options for poorly treated and debilitating diseases either by cell replacement therapies or by identification of drugs using high-throughput stem cell cultures differentiated into specific mature cell types. This promising technology is based on isolation of pluripotent cells that can be expanded in culture and differentiated into a mature phenotype. In addition to the social and political considerations, many methodological issues, such as choice of cell type, culture and differentiation methods, stability of cells in culture, and transplantation techniques, remain. This chapter reviews these issues and presents some novel potential applications.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Preston, S. L., Alison, M. R., Forbes, S. J., Direkze, N. C., Pousom, R., and Wright, N. A. (2003) The new stem cell biology: something for everyone. J. Clin. Pathol: Mol. Pathol. 56, 86–96.
Watt, F. M. and Hogan, B. L. (2000) Out of Eden: stem cells and their niches. Science 287, 1427–1430.
Stacey, G. N., Cobo, F., Nieto, A., Talavera, P., Healy, L., and Concha, A. (2006) The development of ‘feeder’ cells for the preparation of clinical grade hES cell lines: challenges and solutions. J. Biotechnol. 125, 583–588.
Regenerative Medicine 2006. (2006) Department of Health and Human Services. August, http://stemcells.nih.gov/info/scireport/2006report.htm
Pouton, C. W. and Hayes, J. M. (2005) Pharmaceutical applications of embryonic stem cells. Adv. Drug Deliv. Rev. 57, 1918–1934.
Maitra, A., Arking, D. E., Shivapurkar, N., et al. (2005) Genomic alterations in cultured human embryonic stem cells. Nat. Genet. 37, 1099–1103.
NIH Human Embryonic Stem Cell Registry (continually updated), National Institutes of Health, http: //stemcells.nih.gov/research/registry/defaultpage.asp.
Hochedlinger, K. and Jaenisch, R. (2006) Nuclear reprogramming and pluripotency. Nature 441, 1061–1067.
Park, P. C., Selvarajah, S., Bayani, J., Zielenska, M., and Squire, J. A. (2006) Stem cell enrichment approaches. Semin. Cancer Biol. Apr 29 (epub ahead of print).
Fillmore, H. L., Holloway, K. L., and Gillies, G. T. (2005) Cell replacement efforts to repair neuronal injury: a potential paradigm for the treatment of Parkinson’s disease. Neurorehabilitation 20, 233–242.
Walton, N. M., Sutter, B. M., Chen, H. X., et al. (2006) Derivation and large-scale expansion of multipotent astroglial neural progenitors from adult human brain. Development 133(18), 3671–3681.
Kassem, M. (2006) Stem Cells. Potential therapy for age-related diseases. Ann. N. Y. Acad. Sci. 1067, 436–442.
Harris, R. G., Herzog, E. L., Ruscia, E. M. B., Grove, J. E., Van Arname, J. S., and Krause, D. S. (2004) Lack of a fusion requirement for development of bone marrowderived epithelia. Science 305, 90–94.
Hook, L., O’Brien, C., and Allsopp, T. (2005) ES cell technology: An introduction to genetic manipulation, differentiation, and therapeutic cloning. Adv. Drug Deliv. Rev. 57, 1904–1917.
Keller, G. (2005) Embryonic stem cell differentiation: emergence of a new era in biology and medicine. Genes Dev. 19, 1129–1155.
De Angelis, E., Moss, S. H., and Pouton, C. W. (1996) Endothelial cell biology and culture methods for drug transport studies. Adv. Drug Deliv. Rev. 18, 193–218.
Tuma, P. L. and Hubbard, A. L. (2003) Transcytosis: crossing Cellular Barriers. Phys. Rev. 83, 871–932.
Buesen, R., Visan, A., Genschow, E., Slawik, B., Spielmann, H., and Seiler, A. (2004) Trends in improving the embryonic stem cell test (EST): an overview. ALTEX 21, 15–22.
Scholz, G., Genschow, E., Pohl, I., et al. (1999) Prevalidation of the embryonic stem cell test (EST) —a new in vitro embryotoxicity test. Toxicol. In Vitro 13, 675–681.
Spielmann, H., Pohl, I., Döring, B., Liebsch, M., and Moldenhauer, F. (1997) The embryonic stem cell test (EST), an in vitro embryotoxicity test using two permanent mouse cell lines: 3T3 fibroblasts and embryonic stem cells. In Vitro Toxicol. 10, 119–127.
Rohwedel, J., Guan, K., Hegert, C. and Wobus, A. M. (2001) Embryonic stem cells as an in vitro model for mutagenicity, cytotoxicity and embryotoxicity studies: present state and future prospects. Toxicol. In Vitro 15, 741–753.
Wobus, A. M. and Boheler, K. (2005) Embryonic stem cells: Prospects for developmental biology and cell therapy. Physiol. Rev. 85, 635–678.
Torrance, C. J., Agrawal, V., Vogelstein, B., and Kinzler, K. W. (2001) Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat. Biotechnol. 19, 940–945.
Defer, G. L., Geny, C., Ricolfi, F., et al. (1996) Long-term outcome of unilaterally transplanted Parkinsonian patients: I. clinical approach. Brain 119, 41–50.
Lindvall, O., Kokaia, Z., and Martinez-Serrano, A. (2004) Stem cell therapy for human neurodegenerative disorders—how to make it work. Nat. Med. 10, S42–S50.
Menendez, P., Want, L., and Bhatia, M. (2005) Genetic manipulation of human embryonic stem cells: a system to study early human development and potential therapeutic applications. Curr. Gene Ther. 5, 375–385.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Fillmore, H.L., Wu-Pong, S. (2008). Stem Cell Technology and Drug Development. In: Wu-Pong, S., Rojanasakul, Y. (eds) Biopharmaceutical Drug Design and Development. Humana Press. https://doi.org/10.1007/978-1-59745-532-9_9
Download citation
DOI: https://doi.org/10.1007/978-1-59745-532-9_9
Publisher Name: Humana Press
Print ISBN: 978-1-58829-716-7
Online ISBN: 978-1-59745-532-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)